Segments (Tables)

12 Months Ended

Dec. 31, 2022

a. Segment information:


	Year ended December 31,
	2022
	North America			Europe			International Markets
	(U.S. $ in millions)
Revenues	$	7,452		$	4,525		$	1,903
Gross profit		3,926			2,700			1,033
R&D expenses		532			213			72
S&M expenses		941			748			405
G&A expenses		474			246			119
Other income		(15	)		(3	)		(43	)

Segment profit	$	1,993		$	1,496		$	479


	Year ended December 31,
	2021
	North America			Europe			International Markets
	(U.S. $ in millions)
Revenues	$	7,809		$	4,886		$	2,032
Gross profit		4,226			2,823			1,118
R&D expenses		618			244			68
S&M expenses		988			846			417
G&A expenses		427			244			109
Other income		(31	)		(5	)		(5	)

Segment profit	$	2,224		$	1,494		$	529


	Year ended December 31,
	2020
	North America			Europe			International Markets
	(U.S. $ in millions)
Revenues	$	8,447		$	4,757		$	2,154
Gross profit		4,489			2,666			1,096
R&D expenses		622			247			70
S&M expenses		1,013			830			427
G&A expenses		443			261			136
Other income		(10	)		(3	)		(11	)

Segment profit	$	2,421		$	1,331		$	474

Schedule Of Consolidated Income Before Income Tax


	Year ended
	December 31,
	2022			2021		2020
	(U.S. $ in millions)
North America profit	$	1,993		$	2,224	$	2,421
Europe profit		1,496			1,494		1,331
International Markets profit		479			529		474

Total reportable segments profit		3,968			4,246		4,225
Profit of other activities		172			154		163

Total segments profit		4,140			4,401		4,388
Amounts not allocated to segments:
Amortization		732			802		1,020
Other assets impairments, restructuring and other items		414			341		479
Goodwill impairment		2,045			—		4,628
Intangible asset impairments		355			424		1,502
Legal settlements and loss contingencies		2,082			717		60
Other unallocated amounts		610			402		271
Consolidated operating income (loss)		(2,099	)		1,716		(3,572	)

Financial expenses, net		966			1,058		834

Consolidated income (loss) before income taxes	$	(3,065	)	$	658	$	(4,406	)

Schedule of Net Sales by Product Line

The following tables present revenues by major products and activities for each segment for the year ended December 31, 2022, 2021 and 2020:

North America segment:


	Year ended December 31,
	2022		2021		2020
	(U.S. $ in millions)
Generic products	$	3,549	$	3,769	$	4,010
AJOVY		218		176		134
AUSTEDO		963		802		637
BENDEKA and TREANDA		316		385		415
COPAXONE		387		577		884
Anda		1,471		1,323		1,462
Other		549		777		905

Total	$	7,452	$	7,809	$	8,447

Europe segment:


	Year ended December 31,
	2022		2021		2020
	(U.S. $ in millions)
Generic products	$	3,466	$	3,569	$	3,513
AJOVY		124		87		31
COPAXONE		268		391		400
Respiratory products		273		356		353
Other		393		483		459

Total	$	4,525	$	4,886	$	4,757

International Markets segment:


	Year ended December 31,
	2022		2021		2020
	(U.S. $ in millions)
Generic products	$	1,586	$	1,649	$	1,792
AJOVY		35		50		18
COPAXONE		36		37		53
Other		246		295		291

Total	$	1,903	$	2,032	$	2,154

Schedule of Sales Percentage by Therapeutic Category

The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2022, 2021 and

2020.


	Percentage of Third Party Net Sales
	2022			2021			2020
McKesson Corporation		10	%		11	%		12	%
AmerisourceBergen Corporation		10	%		11	%		12	%

Schedule of Property, Plant and Equipment by Geographic Location


	December 31,
	2022		2021
	(U.S. $ in millions)
Israel	$	1,401	$	1,543
Germany		1,143		1,045
United States		625		692
Croatia		445		481
Czech republic		318		324
Hungary		294		321
Ireland		268		269
Other		1,245		1,307

Total property, plant and equipment	$	5,739	$	5,982